Contra-indications, warnings, etc
Vetmedin capsules should not be used in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is not possible for functional or anatomical reasons (e.g. aortic stenosis). The product should only be used in dogs with cardiac insufficiency.
A moderate positive chronotropic effect and vomiting may occur in rare cases. However, these cases are dose-dependent and may be avoided by reducing the dose.
In studies with rats and rabbits, pimobendan had no effect on fertility and embryotoxic effects occurred only at maternotoxic doses. In experiments with rats it has been shown that pimobendan is excreted into milk. No information is available on the safety of Vetmedin in pregnant and lactating bitches.
The pimobendan-induced increase in contractility of the heart is attenuated in the presence of the calcium antagonist verapamil and the ß-antagonist propranolol. In pharmacological studies no interaction between the cardiac glycoside ouabain and pimobendan was detected.
In the case of overdose, symptomatic treatment should be initiated.
Dispose of used packaging in the household refuse. Unused product should be returned to the Veterinary Surgeon.
For animal treatment only.
Pharmaceutical precautions
Do not store above 25°C.
Store in a dry place.
Keep out of reach of children.
Legal category
POM-V (previously POM)
Further information
Pimobendan, a benzimidazole-pyridazinone derivative, is a non-sympathomimetic, non-glycoside inotropic substance with potent vasodilatative properties. It increases calcium sensitivity of cardiac myofilaments and inhibits phosphodiesterase (type III). It also exhibits a vasodilatory action through inhibition of phosphodiesterase III activity.
As the bioavailability of pimobendan is considerably reduced when administered with or shortly after food, it is recommended that animals are treated approximately 1 hour before feeding.
